Switzerland is often perceived as a “small market” – which sometimes leads to one of two extremes: being deprioritised, or being overengineered from day one. Based on our experience, successful rare disease launches in Switzerland are not about size or complexity, but about making the right decisions at the right time. A smart entry to the Swiss market takes a holistic view and considers: Swissmedic regulatory requirements market access pathways and reimbursement strategy lea

The number of clients that have placed their confidence in Swizzard has grown steadily over the past five years. Today, we’re proud to have worked with 40 visionary biotech and pharma companies as they navigate the Swiss landscape. As momentum picks up and Swizzard’s client base continues to grow, our role is unchanged: we’re committed to bringing decision-ready insights, pragmatic options, strategic advice and measurable results. From market shaping and access planning to la

We’re celebrating five years of Swizzard! Swizzard was founded at the beginning of 2021 with a clear ambition: to help bring medical breakthroughs to Swiss patients. Today, we’re proud of what we’ve achieved thanks to our innovative clients and an exceptional team. Together, we’ve helped 39 biotech companies establish and grow their Swiss presence, advancing innovations across oncology, metabolism, dermatology, neurology and beyond, with a strong focus on rare diseases. Alo